# A Study of Equfina® on the Incidences of Adverse Drug Reactions in Participants With Parkinson's Disease (Including Participants With Hepatic Impairment)

> **NCT04724109** · — · COMPLETED · sponsor: **Eisai Co., Ltd.** · enrollment: 1088 (actual)

## Conditions studied

- Parkinson Disease

## Interventions

- **DRUG:** Equfina

## Key facts

- **NCT ID:** NCT04724109
- **Lead sponsor:** Eisai Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-14
- **Primary completion:** 2022-10-13
- **Final completion:** 2022-10-13
- **Target enrollment:** 1088 (ACTUAL)
- **Last updated:** 2022-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04724109

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04724109, "A Study of Equfina® on the Incidences of Adverse Drug Reactions in Participants With Parkinson's Disease (Including Participants With Hepatic Impairment)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04724109. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*